We serve Chemical Name:5-(Bromoacetyl)-1,3-dihydro-2H-indol-2-one CAS:105316-98-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5-(Bromoacetyl)-1,3-dihydro-2H-indol-2-one
CAS.NO:105316-98-1
Synonyms:2H-Indol-2-one, 5-(2-bromoacetyl)-1,3-dihydro-;5-bromoacetyloxindole;5-(Bromoacetyl)-1,3-dihydro-2H-indol-2-one
Molecular Formula:C10H8BrNO2
Molecular Weight:254.080
HS Code:2933790090
Physical and Chemical Properties:
Melting point:225ºC
Boiling point:459.4±45.0 °C at 760 mmHg
Density:1.6±0.1 g/cm3
Index of Refraction:1.625
PSA:46.17000
Exact Mass:252.973831
LogP:1.43
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2H-Indol-2-one, 5-(2-bromoacetyl)-1,3-dihydro- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-(Bromoacetyl)-1,3-dihydro-2H-indol-2-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2H-Indol-2-one, 5-(2-bromoacetyl)-1,3-dihydro- Use and application,5-bromoacetyloxindole technical grade,usp/ep/jp grade.
Related News: Complete the research and development of APIs and intermediates, design new patented process routes, and explore new crystal forms. 5-(Bromoacetyl)-1,3-dihydro-2H-indol-2-one manufacturer Active pharmaceutical ingredients affect the structure and function of the human body. Inactive ingredients in a pharmaceutical may be referred to as bulk pharmaceutical chemicals (BPCs). 5-(Bromoacetyl)-1,3-dihydro-2H-indol-2-one supplier Active pharmaceutical ingredients affect the structure and function of the human body. Inactive ingredients in a pharmaceutical may be referred to as bulk pharmaceutical chemicals (BPCs). 5-(Bromoacetyl)-1,3-dihydro-2H-indol-2-one vendor Darzalex has its own VRd combo trials, dubbed PERSEUS and CEPHEUS, which are testing a newly approved under-the-skin version of the J&J drug called Darzalex Faspro. The CEPHEUS trial appears to have just completed its primary analysis, according to a listing on ClinicalTrials.gov. 5-(Bromoacetyl)-1,3-dihydro-2H-indol-2-one factory Complete the research and development of APIs and intermediates, design new patented process routes, and explore new crystal forms.
